Newsletter
Q1 and Not Done
This being a leap year, EpicentRx leapt into action in Q1. In January, which is named after the two-faced Roman God, Janus, who focused...
The Drive to ‘25
The drive to 2025 is underway! With 2023 in the rear-view mirror, we at EpicentRx look ahead not only to 2024 but also to 2025 when we expect...
No “Fall” in Activity for EpicentRx After Summer
A busy Fall “leaves” little to no downtime for EpicentRx Summer slowdown? What summer slowdown? EpicentRx kicked off the Fall season in high gear...
Q2 Highlights from ASCO, BIO and beyond
As you may have noticed, EpicentRx is a company on the move. From the award of FDA Fast Track status for RRx-001 as an anti-oral mucositis agent to...